Balyasny Asset Management
PBYI icon

Balyasny Asset Management’s Puma Biotechnology PBYI Stock Holding History

Balyasny Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,709
Closed -$173K – 2976
2024
Q1 		$173K Sell
32,709
-48,943
-60% -$264K ﹤0.01% 2441
2023
Q4 		$354K Buy
+81,652
New +$271K ﹤0.01% 2095
2022
Q4 		– Sell
-13,851
Closed -$33K – 3120
2022
Q3 		$33K Buy
+13,851
New +$40.4K ﹤0.01% 2523
2019
Q3 		– Sell
-94,836
Closed -$1.21M – 1476
2019
Q2 		$1.21M Buy
94,836
+40,655
+75% +$936K 0.01% 1027
2019
Q1 		$2.1M Buy
54,181
+13,774
+34% +$421K 0.01% 804
2018
Q4 		$822K Sell
40,407
-399,962
-91% -$12M 0.01% 958
2018
Q3 		$20.2M Buy
440,369
+277,994
+171% +$13.4M 0.09% 300
2018
Q2 		$9.6M Sell
162,375
-102,595
-39% -$5.95M 0.04% 501
2018
Q1 		$18M Buy
264,970
+210,097
+383% +$15.7M 0.08% 351
2017
Q4 		$5.42M Sell
54,873
-132,886
-71% -$14.9M 0.02% 831
2017
Q3 		$22.5M Buy
+187,759
New +$17.5M 0.09% 297
2016
Q4 		– Sell
-124,028
Closed -$8.32M – 1453
2016
Q3 		$8.32M Buy
+124,028
New +$6.27M 0.05% 422
2016
Q2 		– Sell
-33,713
Closed -$990K – 1376
2016
Q1 		$990K Sell
33,713
-229,573
-87% -$10.4M 0.01% 772
2015
Q4 		$20.6M Buy
+263,286
New +$20.7M 0.14% 201
2014
Q3 		– Sell
-32,087
Closed -$2.12M – 829
2014
Q2 		$2.12M Buy
+32,087
New +$2.28M 0.02% 523
2013
Q4 		– Sell
-83,234
Closed -$4.47M – 598
2013
Q3 		$4.47M Buy
83,234
+47,967
+136% +$2.59M 0.06% 362
2013
Q2 		$1.56M Buy
+35,267
New +$1.24M 0.03% 455

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's PBYI Position: Q2 2024 in Review

Balyasny Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 32,709 shares — an estimated $173K sold.

Balyasny Asset Management first reported a position in PBYI in Q2 2013 and held it in 17 quarters. The position peaked at $22.5M in Q3 2017. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Balyasny Asset Management reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 32,709 Puma Biotechnology shares in Q2 2024, an estimated $173K.
  • Balyasny Asset Management first reported a position in Puma Biotechnology in Q2 2013 and held it in 17 quarters.
  • Balyasny Asset Management's Puma Biotechnology position peaked at $22.5M in Q3 2017.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.